PARD
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2011 Q3 | -2.40 | $0 | -$2M |
| 2011 Q2 | -2.80 | $0 | -$2M |
| 2011 Q1 | -2.40 | $0 | -$2M |
| 2010 Q4 | -4.09 | $0 | -$5M |
| 2010 Q3 | -5.20 | $0 | -$4M |
| 2010 Q2 | -5.60 | $0 | -$7M |
| 2010 Q1 | -11.60 | $0 | -$8M |
| 2009 Q4 | -13.42 | $0 | -$8M |